Evidence map›Paper›PMID 39113701›Full record

ArticleInternational journal of biological sciences2024

Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy.

Weikang Xu, Minli Hu, Xinyu Lu, Yueqiong Lao, Na Ma, Yiyue Wang, Jing Li, Xingyuan Chen, Shiming Liu, Jing Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weikang XuDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Minli HuDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Xinyu LuDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research; Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Key Laboratory of Viral Hepatitis Research; Guangdong Provincial Clinical Research Center for Viral Hepatitis; Guangdong Institute of Hepatology. Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yueqiong LaoDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Na MaDepartment of Pathology, The First People's Hospital of Foshan, Foshan 528000, China.
Yiyue WangDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research; Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Key Laboratory of Viral Hepatitis Research; Guangdong Provincial Clinical Research Center for Viral Hepatitis; Guangdong Institute of Hepatology. Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Jing LiDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Xingyuan ChenDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Shiming LiuGuangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Jing LiuDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.
Wei ZhuDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research; Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Key Laboratory of Viral Hepatitis Research; Guangdong Provincial Clinical Research Center for Viral Hepatitis; Guangdong Institute of Hepatology. Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Hui YangDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells play important roles in antitumor immunity. However, given that the hepatocellular carcinoma (HCC) tumor microenvironment confers resistance to T cell-based immunotherapies, novel strategies to boost T cell-mediated antitumor efficacy are urgently needed for the treatment of HCC. Here, we show that high proprotein convertase subtilisin/kexin type9 (PCSK9) expression was negatively associated with HCC patient's overall survival and markers of CD8

Indexed as

Carcinoma, HepatocellularCD8-Positive T-LymphocytesImmunotherapyLiver NeoplasmsProprotein Convertase 9AnimalsCell Line, TumorHumansMaleMiceMice, Inbred C57BLPCSK9 InhibitorsProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellTumor MicroenvironmentPCSK9 InhibitorsPCSK9 protein, humanProgrammed Cell Death 1 ReceptorProprotein Convertase 9Receptors, Antigen, T-Cellhepatocellular carcinoma (HCC)low-density lipoprotein receptor (LDLR)proprotein convertase subtilisin/kexin 9 (PCSK9)TCR-engineered T cell (TCR-T)

Identifiers

PMID39113701
PMCPMC11302870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.